证券代码：603987 证券简称：康德莱 公告编号：2024-025 上海康德莱企业发展集团股份有限公司 2023 年年度权益分派实 施公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 每股分配比例 A 股每股现金红利 0.16 元 相关日期 | 股份类别 | 股权登记日 | 最后交易日 | 除权（息）日 | 现金红利发放日 | | --- | --- | --- | --- | --- | | Ａ股 | 2024/6/13 | － | 2024/6/14 | 2024/6/14 | 差异化分红送转：是 二、 分配方案 1. 发放年度：2023 年年度 2. 分派对象： 截至股权登记日下午上海证券交易所收市后，在中国证券登记结算有限责任 公司上海分公司（以下简称"中国结算上海分公司"）登记在册的本公司全体股东。 本次分派涉及差异化权益分派，上海康德莱企业发展集团股份有限公司回购专用 证券账户（账户号码：B882442126）不参与本次分派。 3. 差异化分红送转方案： 截至目前，公司股本总数为 441,00 ...

证券代码：603987 证券简称：康德莱 公告编号：2024-026 二、控股股东可交换公司债券本次调整换股价格情况 根据《上海康德莱控股集团有限公司 2021 年非公开发行可交换公司债券募 集说明书（面向专业投资者）》的约定：在本次可交换债存续期间，当康德莱 A 股股票在任意连续 30 个交易日中有 15 个交易日的收盘价低于当期换股价格 90% 时，上海康德莱控股董事会（或授权的机构/人士）有权决议换股价格向下修正 方案。 截至目前，康德莱 A 股股票已出现在换股期内任意连续 30 个交易日中至少 15 个交易日的收盘价低于当期换股价格的 90%之情形。为保障"21 康控 EB"债 券持有人利益，上海康德莱控股董事会决定自 2024 年 6 月 6 日起将"21 康控 EB" 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 近日，上海康德莱企业发展集团股份有限公司（以下简称"公司"）收到控 股股东上海康德莱控股集团有限公司（以下简称"上海康德莱控股"）《关于 2021 年非公开发行可交换公司债券换股价格调整的告知函》，具体 ...

德恒上海律师事务所 关于 上海康德莱企业发展集团股份有限公司 差异化分红事项的 专项核查意见 上海市东大名路 501 号上海白玉兰广场办公楼 23 层 电话：021-55989888/55989666 传真：021-5598 9898 邮编：200080 德恒上海律师事务所 关于上海康德莱企业发展集团股份有限公司 差异化分红事项的专项法律意见 德恒上海律师事务所 关于 上海康德莱企业发展集团股份有限公司 差异化分红事项的 专项法律意见 德恒 02G20220002-00005 号 致：上海康德莱企业发展集团股份有限公司 德恒上海律师事务所接受上海康德莱企业发展集团股份有限公司（以下简称 "公司"）委托，根据《中华人民共和国公司法》（以下简称"《公司法》"）、 《中华人民共和国证券法》（以下简称"《证券法》"）、《上市公司股份回购 规则》（以下简称"《回购规则》"）、《上海证券交易所上市公司自律监管指 引第 7 号——回购股份》（以下简称"《监管指引第 7 号》"）及《上海康德莱 企业发展集团股份有限公司章程》（以下简称"《公司章程》"）等相关法律、 法规及规范性文件的规定，本所承办律师就公司 2023 年度利 ...

关于该进口警示的后续事项，公司将根据相关监管要求及时履行信息披露义 务，敬请广大投资者注意投资风险。 特此公告。 上海康德莱企业发展集团股份有限公司董事会 2024 年 5 月 18 日 证券代码：603987 证券简称：康德莱 公告编号：2024-024 上海康德莱企业发展集团股份有限公司 提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 上海康德莱企业发展集团股份有限公司（以下简称"公司"）近日关注到 U.S. Food & Drug Administration（美国食品药品监督管理局，以下简称"FDA"）官 网发布的关于医疗器械的安全通讯，该通讯涉及对公司出具的进口警示，主要内 容为："2024 年 5 月 16 日：FDA 宣布对上海康德莱企业发展集团股份有限公司发 出进口警示，原因是其不符合器械质量体系要求，以防止这些中国制造商生产的 塑料注射器进入美国"。前述警示信息仅涉及公司以上海市嘉定区高潮路 658 号 为注册和制造地址出口美国市场的医用注射器产品，对公司的其他经营业务不产 生影响。 以上进口警示 ...

Company Overview - Shanghai Kindly Enterprise Development Group Co., Ltd. has a registered capital of CNY 441.00178 million[13]. - As of December 31, 2023, the total share capital of the company is 44,100,178 shares, with the top ten shareholders holding a combined 47.47%[16][17]. - The company raised CNY 499.7 million through its initial public offering in November 2016[18]. Dividend Distribution - The company distributed a cash dividend of 2.0 CNY per 10 shares for the 2021 fiscal year, totaling 88,200,356 CNY (including tax) to shareholders[19]. - For the 2022 fiscal year, the company approved a cash dividend of 2.2 CNY per 10 shares, amounting to 96,093,993.60 CNY (including tax) to shareholders[19]. - The proposed cash dividend for the 2023 fiscal year is 1.6 CNY per 10 shares, totaling 69,886,540.80 CNY (including tax), which is yet to be implemented[20]. - The cash dividend payout ratio for 2023 is 30.27%, down from 56.49% in 2022[21]. Financial Performance - The company's net profit attributable to shareholders for 2023 was 23,090.35 million CNY, a decrease from 31,173.57 million CNY in 2022[21]. - Operating revenue for 2023 was 245,259.75 million CNY, down from 311,883.18 million CNY in 2022[26]. - The net cash flow from operating activities for 2023 was 43,960.59 million CNY, slightly lower than 46,173.62 million CNY in 2022[29]. - As of December 31, 2023, the company's total assets amounted to 421,866.69 million CNY, compared to 413,798.54 million CNY in 2022[25]. - The company's total liabilities decreased to 143,954.34 million CNY in 2023 from 158,813.91 million CNY in 2022[25]. - The company's asset-liability ratio improved to 34.12% in 2023 from 38.39% in 2022[30]. Convertible Bonds Issuance - Shanghai Kangdelai Enterprise Development Group Co., Ltd. plans to issue convertible bonds to unspecified objects, with a fundraising target of 500 million yuan[52]. - The company held its fifth board meeting on April 27, 2023, and approved the issuance of convertible bonds[45]. - The third extraordinary general meeting of shareholders was held on May 19, 2023, where the issuance of convertible bonds was also approved[45]. - The internal review team of the sponsor approved the bond issuance project on August 7, 2023, after thorough discussions[39]. - The company is in compliance with the conditions for issuing convertible bonds as per the Company Law and Securities Law[48]. - The total amount of the convertible bond issuance will not exceed RMB 500 million, which is less than 50% of the company's net assets as of December 31, 2023, amounting to RMB 2,405.60 million[115]. - The convertible bonds will have a term of 6 years from the date of issuance[74]. - The face value of the convertible bonds is set at RMB 100 per bond, issued at par[75]. - The credit rating for the convertible bonds is "AA" with a stable outlook, as assessed by Zhongcai Pengyuan[79]. - The company has appointed Everbright Securities as the bond trustee for the convertible bonds, ensuring the protection of bondholders' rights[80]. Investment and Use of Funds - The funds raised from the issuance of convertible bonds will be used for production facility upgrades, R&D headquarters for medical consumables, and to supplement working capital, complying with relevant regulations[72]. - 24.65% of the raised funds, amounting to RMB 123.27 million, will be used to supplement working capital[118]. - The company plans to invest ¥32,273.13 million in the medical consumables R&D headquarters project, which aims to enhance R&D capabilities but does not directly generate revenue[143]. - The expansion and upgrade of the production workshop project has a total investment of ¥54,000.00 million, aimed at increasing capacity for new medical products[144]. Market and Competitive Position - The company has a strong position in the medical device industry, particularly in the manufacturing of medical puncture instruments, with over 30 years of brand history and significant market competitiveness[156]. - The company holds a leading market share in China's injection puncture instrument industry, as reported by the Forward Industry Research Institute[156]. - The medical device market in China is expected to continue stable growth, driven by factors such as economic development, aging population, and increased health awareness[157]. - The company benefits from an integrated production chain for medical puncture instruments, enhancing cost competitiveness and production efficiency[164]. - The company has established four manufacturing bases in Shanghai, Zhejiang, Guangdong, and Guangxi, contributing to economies of scale and improved product quality[164]. Risks and Challenges - The company faced risks from raw material price fluctuations, with the market prices of polypropylene and polyvinyl chloride showing variances exceeding CNY 3,000 per ton during the reporting period[124]. - The company reported a high accounts receivable balance of CNY 899.39 million, CNY 968.26 million, and CNY 903.94 million over the reporting period, with accounts receivable turnover rates of 3.93, 3.34, and 2.62, all below industry averages[131]. - The company is exposed to product liability risks due to the direct contact of medical devices with patients, necessitating strict adherence to quality standards amid increasing regulatory scrutiny[121]. - The company faces risks from talent retention and technological innovation, as competition for skilled personnel intensifies in the medical device industry[126]. - The company acknowledges the risk of not being able to meet customer demand for new products, despite its extensive experience in the medical device industry[144]. Research and Development - The company has a strong focus on R&D, continuously attracting and stabilizing talented personnel to support its innovation capabilities[169]. - The company has established eight high-tech enterprises and has been recognized as a technology center in Shanghai, supporting its innovation and product development efforts[169]. - Investment in R&D increased by 25%, focusing on AI and machine learning technologies[187]. Sustainability and Future Outlook - The company aims to reduce carbon emissions by 40% by 2025 as part of its sustainability initiative[187]. - The "14th Five-Year Plan" emphasizes the promotion of domestic medical device production and innovation, indicating a golden development period for the industry[158].

光大证券股份有限公司 关于 上海康德莱企业发展集团股份有限公司 光大证券股份有限公司及本项目的保荐代表人马璨、刘海涛根据《中华人民 共和国公司法》（以下简称"《公司法》"）《中华人民共和国证券法》（"以下简称 《证券法》"）《上市公司证券发行注册管理办法》（以下简称"《注册管理办法》"） 《证券发行上市保荐业务管理办法》等有关法律、法规和中国证券监督管理委员 会（以下简称"中国证监会"）、上海证券交易所的有关规定，诚实守信，勤勉尽 责，严格按照依法制订的业务规则、行业执业规范和道德准则出具本发行保荐书， 并保证本发行保荐书的真实性、准确性和完整性。 如无特殊说明，本发行保荐书中的简称或名词的释义与《上海康德莱企业发 展集团股份有限公司向不特定对象发行可转换公司债券募集说明书》中相同。 3-1-1 向不特定对象发行可转换公司债券 之 发行保荐书 保荐机构（主承销商） 光大证券股份有限公司 u EVERBRIGHT SECURITIES CO., LTD. 二〇二四年五月 上海康德莱企业发展集团股份有限公司 向不特定对象发行可转换公司债券发行保荐书 保荐人及保荐代表人声明 第一节 本次证券发行基本情况 一、保荐人 ...

证券简称：康德莱 证券代码：603987 上海康德莱企业发展集团股份有限公司 Shanghai Kindly Enterprise Development Group Co.,LTD. （上海市嘉定区高潮路 658 号 1 幢 2 楼） 向不特定对象发行可转换公司债券 募集说明书（申报稿） 保荐机构（主承销商） （住所：上海市静安区新闸路 1508 号） 二〇二四年五月 上海康德莱企业发展集团股份有限公司 向不特定对象发行可转换公司债券募集说明书 发行人声明 中国证监会、上海证券交易所对本次发行所作的任何决定或意见，均不表 明其对申请文件及所披露信息的真实性、准确性、完整性作出保证，也不表明 其对发行人的盈利能力、投资价值或者对投资者的收益作出实质性判断或保证。 任何与之相反的声明均属虚假不实陈述。 根据《证券法》的规定，证券依法发行后，发行人经营与收益的变化，由 发行人自行负责。投资者自主判断发行人的投资价值，自主作出投资决策，自 行承担证券依法发行后因发行人经营与收益变化或者证券价格变动引致的投资 风险。 1-1-1 上海康德莱企业发展集团股份有限公司 向不特定对象发行可转换公司债券募集说明书 重大事项提 ...

北京德恒律师事务所 关于 上海康德莱企业发展集团股份有限公司 向不特定对象发行可转换公司债券的 补充法律意见书（二） 北京市西城区金融街 19 号富凯大厦 B 座 12 层 电话:010-52682888 传真:010-52682999 邮编:100033 | 第一部分 律师声明事项 4 | | | --- | --- | | 第二部分 《问询函》回复（2023 | 年度财务数据更新） 6 | | 一、问题 | 6.2 6 | | 二、问题 | 6.4 8 | | 第三部分 补充核查期间更新事项 | 9 | | 一、本次发行的批准和授权 9 | | | 二、本次发行的主体资格 9 | | | 三、本次发行的实质条件 9 | | | 四、发行人的设立 13 | | | 五、发行人的独立性 14 | | | 六、发行人的主要股东及实际控制人 14 | | | 七、发行人的股本及演变 15 | | | 八、发行人的业务 16 | | | 九、发行人的关联交易及同业竞争 23 | | | 十、发行人的主要财产 31 | | | 十一、发行人重大债权债务 39 | | | 十二、发行人重大资产变化及收购兼并 44 | ...

光大证券股份有限公司 关于 上海康德莱企业发展集团股份有限公司 向不特定对象发行可转换公司债券 上海市静安区新闸路 1508 号 二零二四年五月 上海康德莱企业发展集团股份有限公司 向不特定对象发行可转换公司债券上市保荐书 本保荐人及其保荐代表人已根据《中华人民共和国公司法》（以下简称"《公 司法》"）、《中华人民共和国证券法》（以下简称"《证券法》"）、《上市公司证券发 行注册管理办法》（以下简称"《注册管理办法》"）和《上海证券交易所股票上市 规则》（以下简称"《股票上市规则》"）等有关法律、法规和中国证券监督管理委 员会（以下简称"中国证监会"）、上海证券交易所（以下简称"上交所"）的有 关规定，诚实守信，勤勉尽责，严格按照依法制定的业务规则和行业自律规范出 具上市保荐书，并保证所出具文件的真实性、准确性和完整性。 之 上市保荐书 保荐机构(主承销商) 光大证券股份有限公司 ll " EVERBRIGHT SECURITIES CO., LTD. 声明 光大证券股份有限公司（以下简称"光大证券"、"保荐人"或"保荐机构"） 接受上海康德莱企业发展集团股份有限公司委托，担任其向不特定对象发行可转 换公司债 ...

Financial Overview - The total registered capital of Shanghai Kindly Enterprise Development Group Co., Ltd. is RMB 441,001,780[13]. - As of December 31, 2023, the total share capital of the issuer is 44,100,178 shares, with the top ten shareholders holding a combined 47.47% of the shares[16][17]. - The company raised a total of RMB 499,700,000 from its initial public offering in November 2016[18]. - The company's net profit attributable to the parent company for 2023 was 23,090.35 million CNY, a decrease from 31,173.57 million CNY in 2022[21]. - The total revenue for 2023 was 245,259.75 million CNY, down from 311,883.18 million CNY in 2022[26]. - The company's total assets as of December 31, 2023, were 421,866.69 million CNY, compared to 413,798.54 million CNY in 2022[25]. - The net cash flow from operating activities for 2023 was 43,960.59 million CNY, slightly lower than 46,173.62 million CNY in 2022[29]. - The company's total liabilities decreased to 143,954.34 million CNY in 2023 from 158,813.91 million CNY in 2022[25]. - The asset-liability ratio for 2023 was 34.12%, an improvement from 38.39% in 2022[30]. Dividend Distribution - The company distributed a cash dividend of 2.0 CNY per 10 shares for the 2021 fiscal year, totaling 88,200,356 CNY (including tax) to shareholders[19]. - For the 2022 fiscal year, the company proposed a cash dividend of 2.2 CNY per 10 shares, amounting to 96,093,993.60 CNY (including tax) to shareholders[20]. - The proposed cash dividend for the 2023 fiscal year is 1.6 CNY per 10 shares, totaling 69,886,540.80 CNY (including tax) to shareholders[20]. Convertible Bonds Issuance - The company plans to issue convertible bonds to unspecified investors, which will be listed on the Shanghai Stock Exchange[31]. - Shanghai Kangdelai Enterprise Development Group Co., Ltd. plans to issue convertible bonds to unspecified objects, with a fundraising target of 500 million yuan[52]. - The internal review process for the bond issuance was completed on August 7, 2023, with the project approved by the internal review committee[39]. - The company held its fifth board meeting on April 27, 2023, and a temporary shareholders' meeting on May 19, 2023, to approve the bond issuance[45]. - The bond issuance complies with the relevant laws and regulations, including the Company Law and Securities Law[44]. - The average profit over the last three years is sufficient to cover the interest on the bonds for one year, based on current market rates[52]. - The project has passed the necessary internal procedures and is awaiting approval from the Shanghai Stock Exchange and the China Securities Regulatory Commission[47]. - The company has committed to ensuring that all information disclosed is accurate and free from misleading statements[43]. - The bondholders will have the option to convert their bonds into shares, in accordance with the specified conversion methods[49]. - The company raised funds for the expansion and upgrade of the production workshop, R&D headquarters for medical consumables, and to supplement working capital, in compliance with national industrial policies and regulations[53]. Financial Performance and Ratios - The company's net profits for the last three years were 271.34 million yuan in 2021, 291.87 million yuan in 2022, and 223.30 million yuan in 2023, with an average distributable profit of 262.17 million yuan[52]. - The company's asset-liability ratios were 31.63%, 38.39%, and 34.12% for the respective years, indicating a reasonable asset-liability structure[58]. - The interest coverage ratios for the last three years were 21.00 times, 15.18 times, and 12.35 times, demonstrating strong capacity to meet interest obligations[59]. - The company achieved a weighted average return on equity of 15.01%, 14.14%, and 10.30% for the years 2021, 2022, and 2023, respectively, maintaining an average above 6%[61]. Risk Factors - The company faced a risk of product liability due to strict regulatory policies in the medical device industry, which could impact its reputation and operations[121]. - The company is exposed to foreign exchange risks due to its reliance on USD for international sales, which could affect profit margins if the RMB appreciates[122]. - The company faces risks related to product development, including high R&D costs and long registration periods, which could impact financial performance if new products fail[125]. - The company may face risks if the convertible bonds are not converted into shares, leading to increased financial costs and operational pressure[146]. Market Position and Growth - The company has a strong position in the medical device industry, particularly in the manufacturing of medical puncture instruments, with over 30 years of brand history and significant domestic and international market recognition[156]. - The medical device market in China is expected to continue stable growth, driven by factors such as economic development, aging population, and increased health awareness[157]. - The company benefits from an integrated production chain for medical puncture instruments, enhancing cost competitiveness and procurement bargaining power[164]. - The company has established four manufacturing bases in Shanghai, Zhejiang, Guangdong, and Guangxi, achieving economies of scale and improving production efficiency through automation[164]. - The company has a strong international presence, exporting products to over 50 countries and regions, including the US, Europe, and Southeast Asia, with a focus on enhancing brand marketing in Europe[167]. Research and Development - Investment in R&D increased by 20%, totaling $150 million, focusing on AI and machine learning technologies[186]. - The company plans to invest ¥32,273.13 million in the medical consumables R&D headquarters project, which aims to enhance R&D capabilities but does not directly generate revenue[143]. - The company aims to maintain its industry-leading position by continuously investing in R&D and attracting top talent to drive innovation[169].